Last updated: July 29, 2026
SENJU PHARMACEUTICALS CO., LTD. v. AMNEAL PHARMACEUTICALS LLC (3:18-cv-05571) Litigation Summary, Patent Claims, and Case Posture
SENJU PHARMACEUTICALS CO., LTD. sued AMNEAL PHARMACEUTICALS LLC in 3:18-cv-05571 alleging infringement of SENJU’s Orange Book-listed drug patents tied to a generic launch by AMNEAL. The record reviewed here contains insufficient case-specific detail (asserted patent numbers, claim charts, ANDA number, district court, and asserted counts) to produce a complete litigation summary and patent-by-patent infringement analysis.
What patents were asserted in SENJU v. AMNEAL 3:18-cv-05571?
Answer: Not determinable from the provided information.
Which Orange Book patents were listed as infringed?
Not determinable from the provided information.
Were method-of-use, formulation, or manufacturing patents asserted?
Not determinable from the provided information.
What was AMNEAL’s ANDA and Paragraph IV posture in 3:18-cv-05571?
Answer: Not determinable from the provided information.
What certifications (20–30 months stay triggers) were pleaded?
Not determinable from the provided information.
Did AMNEAL dispute validity, infringement, or both?
Not determinable from the provided information.
What did SENJU allege in its complaint (infringement theory and requested relief)?
Answer: Not determinable from the provided information.
Which claims and which dosage form or strength were targeted?
Not determinable from the provided information.
Was the case framed under 35 U.S.C. § 271(e)(2) (Hatch-Waxman)?
Not determinable from the provided information.
What motions were filed and how did the case progress procedurally?
Answer: Not determinable from the provided information.
Claim construction, summary judgment, or motion to dismiss?
Not determinable from the provided information.
Markman timeline and how it affected infringement or validity arguments
Not determinable from the provided information.
When did the litigation resolve and what was the outcome in 3:18-cv-05571?
Answer: Not determinable from the provided information.
Was there a settlement, consent judgment, or final judgment?
Not determinable from the provided information.
Were any patents held invalid or not infringed?
Not determinable from the provided information.
How did the court rule on patent validity (35 U.S.C. § 102/103/112) in this case?
Answer: Not determinable from the provided information.
Anticipation and obviousness assessments
Not determinable from the provided information.
Indefiniteness, enablement, written description issues
Not determinable from the provided information.
How did the court rule on infringement (doctrine of equivalents or literal infringement)?
Answer: Not determinable from the provided information.
Claim charts: active ingredient, excipients, and process parameters
Not determinable from the provided information.
Design-around arguments
Not determinable from the provided information.
What is the commercial and regulatory impact of this litigation for SENJU and AMNEAL?
Answer: Not determinable from the provided information.
Impact on AMNEAL’s generic launch date
Not determinable from the provided information.
Impact on SENJU’s remaining exclusivity and follow-on strategy
Not determinable from the provided information.
Key Takeaways
- The case caption and docket number (3:18-cv-05571) identify the dispute, but the provided input does not include asserted patent numbers, ANDA details, procedural history, or judgment/settlement terms required for a litigation summary and patent analysis.
- No defensible conclusions can be drawn about infringement theories, validity arguments, or outcome without case-specific record elements.
FAQs
- What court and district handled SENJU v. AMNEAL under 3:18-cv-05571?
- Which ANDA was challenged in SENJU v. AMNEAL 3:18-cv-05571?
- Did SENJU assert formulation patents, method-of-use patents, or both in 3:18-cv-05571?
- What did AMNEAL’s Paragraph IV notice allege about infringement and invalidity?
- What was the final resolution (settlement, dismissal, or judgment) in 3:18-cv-05571?
References (APA)
- Docket: SENJU PHARMACEUTICAL CO., LTD. v. AMNEAL PHARMACEUTICALS LLC, 3:18-cv-05571.
